Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06229665 · ClinicalTrials.gov registry record · Phase 2

Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)

A Phase 2 study of Dry Age-Related Macular Degeneration, sponsored by LumiThera.

Active
Registry status
Phase 2
Development phase
75
Enrollment target
7
Study locations

NCT06229665: Active Phase 2 study of Dry Age-Related Macular Degeneration, sponsored by LumiThera.

NCT06229665 is a Phase 2 study of Dry Age-Related Macular Degeneration that is active but no longer recruiting, run by LumiThera. The registered enrollment target is 75 participants, roughly in line with the 73-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target. The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06229665, a Phase 2 study of Dry Age-Related Macular Degeneration, is active but no longer recruiting, sponsored by LumiThera.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
7
Study locations

Study Summary

This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.

Conditions Studied

Dry Age-Related Macular Degeneration

Interventions

  • DEVICE Valeda Light Delivery System

Study Locations (7)

California

  • Retina Vitreous Associates Medical Group - Beverly Hills
  • Stanford University - Palo Alto

Florida

  • Florida Eye Clinic - Altamonte Springs

Maryland

  • Cumberland Valley Retina Consultants - Hagerstown

New York

  • New York Ear and Eye Infirmary - New York

Texas

  • Gulf Coast Eye Institute - McAllen

Washington

  • Retina Center Northwest - Silverdale

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2023-10-25
Est. Completion 2025-06-01
Phase Phase 2
LumiThera

3 total trials

What the registry record for NCT06229665 still lists

NCT06229665 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, roughly in line with the 73-participant average among 7 other Dry Age-Related Macular Degeneration trials with a reported enrollment target.

The record links to 1 condition, with Dry Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Valeda Light Delivery System is the first listed.

NCT06229665 lists 7 locations in 6 states (California, Florida, Maryland).

Frequently Asked Questions

What is clinical trial NCT06229665 about?

NCT06229665 is a clinical study titled "Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITEIIIB)". This study is an open-label, prospective, multi-center extension study on the continued use of photobiomodulation (PBM) in subjects with dry age-related macular degeneration (AMD) that participated in the CSP005 LIGHTSITE III study.

What is the current status of trial NCT06229665?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2023-10-25. Estimated completion is 2025-06-01.

What conditions does trial NCT06229665 study?

This clinical trial studies the following conditions: Dry Age-Related Macular Degeneration.

What interventions are being tested in trial NCT06229665?

The interventions under investigation include: Valeda Light Delivery System (DEVICE).

Who is sponsoring clinical trial NCT06229665?

This trial is sponsored by LumiThera, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06229665 being conducted?

This trial has 7 study locations across California, Florida, Maryland, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dry Age-Related Macular Degeneration

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06229665, the US trial registry maintained by the National Library of Medicine. NCT06229665 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.